Side effects and toxicities of targeted therapies in stage IV melanoma

American Journal of Therapeutics

Volumn 22, Issue 1, 2015, Pages 44-53

  Ascierto, Paolo A ^a   Bastholt, Lars ^b   Hersey, Peter ^c   Cinat, Gabriela ^d   Eggermont, Alexander M M ^e   Hauschild, Axel ^f   Espinosa, Enrique ^g   Robert, Caroline ^e  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d Instituto de Oncologia Angel H Roffo   (Argentina)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f UNIVERSITY OF KIEL   (Germany)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Melanoma; side effects; stage IV; toxicities

Indexed keywords

B RAF KINASE INHIBITOR; C KIT INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOMODULATING AGENT; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR; PROTEIN KINASE INHIBITOR;

ADVANCED CANCER; ADVERSE DRUG REACTION; ANOREXIA; ARTHRALGIA; CANCER FATIGUE; CANCER INCIDENCE; CANCER PATIENT; CANCER STAGING; CANCER THERAPY; CHILL; COLITIS; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DEHYDRATION; DERMATITIS; DIARRHEA; DRUG TOXICITY; DYSPNEA; ENDOCRINE DISEASE; ENZYME INHIBITION; FAINTNESS; FATIGUE; FEVER; GENE MUTATION; HEADACHE; HEPATITIS; HUMAN; HYPERKERATOSIS; HYPONATREMIA; IMMUNOLOGICAL TOLERANCE; KERATOACANTHOMA; MELANOMA; MYOSITIS; NAUSEA; NEPHRITIS; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RASH; SKIN TOXICITY; UVEITIS; VOMITING; DRUG DESIGN; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SKIN NEOPLASMS;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; IMMUNOLOGIC FACTORS; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; SKIN NEOPLASMS;

EID: 84921433398     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3182a39858     Document Type: Conference Paper

References (37)

1. Eigentler TK, Caroli UM, Radny P, et al. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol. 2003;4:748-759.
2. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291-3310.
3. El-Osta H, Falchook G, Tsimberidou A, et al. BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One. 2011;6:e25806.
4. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
5. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809-819.
6. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707-714.
7. Dalle S, Poulalhon N, Thomas L. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 365:1448-1449; author reply 1450.
8. Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol. 2012;30:2375-2383.
9. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366:207-215.
10. Arnault JP, Wechsler J, Escudier B, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol. 2009;27:e59-e61.
11. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379:1893-1901.
12. Trefzer U, Minor D, Ribas A, et al. BREAK-2: a phase IIA trial of the selective BRAF kinase inhibitor GSK2118436 in patients with BRAF mutation-positive (V600E/K) metastatic melanoma. Pigment Cell Res. 2011;24:1020.
13. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial. Lancet. 2012; 380:358-365.
14. Hauschild A, Grob JJ, Demidov LV, et al. Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600Emutated melanoma. J Clin Oncol. 2012;30(suppl):LBA8500.
15. Haura EB, Ricart AD, Larson TG, et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2010;16:2450-2457.
16. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107-114.
17. Ascierto PA, Berking C, Agarwala SS, et al. Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. J Clin Oncol. 2012;30(suppl):8511.
18. Novartis P. A Phase II Study of Single Agent MEK162 in PatientsWith AdvancedMelanoma; NCT01320085. Bethesda, MD: NCI; 2012. Available at: http://clinicaltrials.gov/ct2/show/NCT01320085. Accessed 5 March, 2012.
19. Ascierto PA, Streicher HZ, Sznol M. Melanoma: a model for testing new agents in combination therapies. J Transl Med. 2010;8:38.
20. Infante JR, Falchook GS, Lawrence DP, et al. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). J Clin Oncol. 2011;29:CRA8503.
21. Flaherty KT, Infante JR, Falchook GS, et al. Phase I/II expansion cohort of BRAF inhibitor GSK2118436 + MEK inhibitor GSK1120212 in patients with BRAF mutant metastatic melanoma who progressed on a prior BRAF inhibitor K. Pigment Cell Res. 2011;24:1022.
22. Weber JS, Flaherty KT, Infante JR, et al. Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma. J Clin Oncol. 2012;30(suppl):8510.
23. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006; 24:4340-4346.
24. Smalley KS, Sondak VK, Weber JS. c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histol Histopathol. 2009;24:643-650.
25. Smalley KS, Nathanson KL, Flaherty KT. Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. Cancer Res. 2009;69:3241-3244.
26. Kong Y, Si L, Zhu Y, et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res. 2011;17:1684-1691.
27. Becker JC, Bröcker EB, Schadendorf D, et al. Imatinib in melanoma: a selective treatment option based on KIT mutation status? J Clin Oncol. 2007;25:e9.
28. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011;29:2904-2909.
29. Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305:2327-2334.
30. Kluger HM, Dudek AZ, McCann C, et al. A phase 2 trial of dasatinib in advanced melanoma. Cancer. 2011;117: 2202-2208.
31. Cho J, Kim K, Kwon M, et al. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs. 2012;30:2008-2014.
32. Calabro L, Danielli R, Sigalotti L, et al. Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications. Semin Oncol. 2010;37:460-467.
33. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol. 2010;37:499-507.
34. Hoos A, Ibrahim R, Korman A, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol. 2010;37: 533-546.
35. Ascierto PA, Marincola FM, Ribas A. Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. J Transl Med. 2011;9:196.
36. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl JMed. 2010;363:711-723.
37. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-2526.